Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
ANR
vs
S
S&P/ASX 300
ANR
Over the past 12 months, ANR has underperformed S&P/ASX 300, delivering a return of -40% compared to S&P/ASX 300's 3% drop.
Stocks Performance
ANR vs S&P/ASX 300
Performance Gap
ANR vs S&P/ASX 300
Performance By Year
ANR vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Anatara Lifesciences Ltd
Glance View
Anatara Lifesciences Ltd. engages in the development of non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. The company is headquartered in Adelaide, South Australia. The company went IPO on 2014-10-16. The firm is engaged in developing evidence-based solutions for gastrointestinal diseases in humans and animals. Its products include Gastrointestinal ReProgramming (GaRP), Detach, BONIFF, and ANR-pf. Its GaRP Product is a microbiome-targeted multi-component complementary medicine, which is designed to address the primary underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Detach is a non-antibiotic approach to aid in the control of diarrheal disease known as scour, which is developed using bromelain. BONIFF is a revised formulation which is applied to dry feed for piglets after weaning, reducing labor input, and simplifying the entire process. ANR-pf is an enriched formulation for poultry in water, designed to allow the full delivery of key additives in a quick and flexible dosing method.
